Nicorette Quickmist 1 mg Oromucosal spray
PDF Leaflet Revision Date: 22 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tobacco dependence in adults.
Dosage (summary)
Up to 4 sprays/hour; max 64 sprays/24 hours.
Onset of Action / Duration
Onset: a few minutes, Duration: varies.
Special Populations
- Renal impairment
- Hepatic impairment
- Cardiovascular disease
- Diabetes mellitus
Pregnancy & Breastfeeding
Use only if benefits outweigh risks; avoid during breastfeeding.
Key Drug Interactions
- May enhance effects of adenosine
- CYP1A2 metabolized drugs
Contraindications
- Hypersensitivity to nicotine
- Children under 18
- Non-smokers
Common side effects
- Headache
- Nausea
- Throat irritation
- Hiccups
Counselling Points
- Use with behavioral support
- Monitor for allergic reactions
- Avoid use in non-smokers
Serious warnings
- Risk of severe toxicity in children
- Caution in cardiovascular disease
Important Disclaimer
The Nicorette Quickmist 1 mg Oromucosal spray professional information leaflet below is the property of Johnson & Johnson and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
